Drugs / iNTS-GMMA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06213506 | Jan 2024 → Sep 2026 expected | salmonellosis | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05480800 Comparator | Sep 2022 → Sep 2024 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNTS-GMMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480800 ↗ |
| Modality | Vaccine | “iNTS-GMMA low dose vaccine” NCT05480800 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06213506 ↗ |